Literature DB >> 1630784

Prevalence of age-related maculopathy. The Beaver Dam Eye Study.

R Klein1, B E Klein, K L Linton.   

Abstract

PURPOSE: The relationships of retinal drusen, retinal pigmentary abnormalities, and macular degeneration to age and sex were studied in 4926 people between the ages of 43 and 86 years who participated in the Beaver Dam Eye Study.
METHODS: The presence and severity of various characteristics of drusen and other lesions typical of age-related maculopathy were determined by grading stereoscopic color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.
RESULTS: One or more drusen were present in the macular area of at least 1 eye in 95.5% of the population. People 75 years of age or older had significantly higher frequencies (P less than 0.01) of the following characteristics than people 43 to 54 years of age: larger sized drusen (greater than or equal to 125 microns, 24.0% versus 1.9%), soft indistinct drusen (23.0% versus 2.1%), retinal pigment abnormalities (26.6% versus 7.3%), exudative macular degeneration (5.2% versus 0.1%), and geographic atrophy (2.0% versus 0%).
CONCLUSION: These data indicate signs of age-related maculopathy are common in people 75 years of age or older and may pose a substantial public health problem.

Entities:  

Mesh:

Year:  1992        PMID: 1630784     DOI: 10.1016/s0161-6420(92)31871-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  458 in total

1.  Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study.

Authors:  S H Sarks; J J Arnold; M C Killingsworth; J P Sarks
Journal:  Br J Ophthalmol       Date:  1999-03       Impact factor: 4.638

2.  "Oxidative protector" enzymes in the macular retinal pigment epithelium of aging eyes and eyes with age-related macular degeneration.

Authors:  R N Frank
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 3.  Macular pigment and age related macular degeneration.

Authors:  S Beatty; M Boulton; D Henson; H H Koh; I J Murray
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

Review 4.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

5.  Cone photopigment in older subjects: decreased optical density in early age-related macular degeneration.

Authors:  Ann E Elsner; Stephen A Burns; John J Weiter
Journal:  J Opt Soc Am A Opt Image Sci Vis       Date:  2002-01       Impact factor: 2.129

6.  Ophthaproblem. Vitamin supplementation.

Authors:  Sanjay Sharma; Gaurav K Shah
Journal:  Can Fam Physician       Date:  2002-03       Impact factor: 3.275

7.  Ophthaproblem. Photodynamic therapy with verteporfin.

Authors:  S Sharma
Journal:  Can Fam Physician       Date:  2001-05       Impact factor: 3.275

Review 8.  Simple and complex ABCR: genetic predisposition to retinal disease.

Authors:  R Allikmets
Journal:  Am J Hum Genet       Date:  2000-09-01       Impact factor: 11.025

9.  Extracts from "clinical evidence": age related macular degeneration.

Authors:  J J Arnold; S H Sarks
Journal:  BMJ       Date:  2000-09-23

10.  Aging of cultured retinal pigment epithelial cells: oxidative reactions, lipofuscin formation and blue light damage.

Authors:  Sven Erik G Nilsson; Staffan P Sundelin; Ulf Wihlmark; Ulf T Brunk
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.